公开(公告)号：WO2023065606A1

公开(公告)日：2023-04-27

申请号：PCT/CN2022/084709

申请日：2022-04-01

申请人： 广州谷森制药有限公司

发明人： 黄才古 ,  邓永华 ,  孙辉

IPC分类号： A61K31/4015 ,  A61K31/4025 ,  C07D207/267 ,  C07D401/12 ,  C07D403/12 ,  C07D497/04 ,  C07D403/14 ,  A61P31/14

摘要： 一种如式I所示的新型氘代氰基类化合物，或其药学上可接受的盐、异构体或前药。以及上述氘代化合物的制备方法、组合物及应用。该类化合物作为3CL蛋白酶抑制剂，在病毒抑制活性相当的基础上，实现了更优的药动学性质和治疗效果，成药性更好，式(I)如下所示：

公开(公告)号：WO2023036093A1

公开(公告)日：2023-03-16

申请号：PCT/CN2022/117124

申请日：2022-09-05

申请人： 广东众生睿创生物科技有限公司

发明人： 陈小新 ,  王晶晶 ,  黄建洲 ,  刘卓伟 ,  龙超峰 ,  陈曙辉 ,  陈新海

IPC分类号： C07D413/12 ,  C07D207/27 ,  A61K31/4015 ,  A61P31/00

摘要： 公开了一类酮酰胺衍生物及其应用，具体公开了式(IV)化合物及其药学上可接受的盐。

公开(公告)号：WO2023002004A1

公开(公告)日：2023-01-26

申请号：PCT/EP2022/070585

申请日：2022-07-22

申请人： LABORATORIOS LESVI, S.L.

发明人： RIDHURKAR, Devendra ,  ÚBEDA PÉREZ, Carmen ,  DÍEZ MARTÍN, Ignacio

IPC分类号： A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61P1/00 ,  A61K31/4015

摘要： The present invention provides an oral solid pharmaceutical composition in the form of a multiparticulate composition comprising an immediate release core comprising levetiracetam or a pharmaceutically acceptable salt thereof coated with a modified release layer, a process for the preparation of the composition of the invention, and its use in therapy.

公开(公告)号：WO2023285072A1

公开(公告)日：2023-01-19

申请号：PCT/EP2022/066656

申请日：2022-06-20

申请人： RECEPTORPHARMA INC S-CORP

发明人： MENSONIDES-HARSEMA, Marguérite ,  RESSAISSI, Zacharia Iskander ,  BRUNMARK, Charlott ,  VON WACHENFELDT, Karin

IPC分类号： A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  C07C69/757 ,  C07D207/38 ,  C07D295/03 ,  A61K31/216 ,  A61K31/4015 ,  A61K31/495 ,  A61K31/4453

摘要： The present invention relates to compound of formula (I), a diastereomer, enantiomer, crystal or co-crystal thereof, or a pharmaceutically acceptable salt, or mixture thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to a process of preparing said compounds as well as to their use as medicaments for the prevention, prophylaxis of progression, and/or treatment of a disease in which an antagonistic effect of the G-protein coupled receptor 3 (GPR3) is beneficial, such as neurogenerative diseases, like dementias, including Alzheimer disease.

公开(公告)号：WO2022231257A1

公开(公告)日：2022-11-03

申请号：PCT/KR2022/005916

申请日：2022-04-26

申请人： 주식회사 케이에스비튜젠

发明人： 김보경 ,  정승효 ,  이경진 ,  김수정

IPC分类号： A61K31/4015 ,  A61P21/04 ,  A23L33/10 ,  A61P21/00

摘要： 본 발명은 옥시라세탐의 새로운 용도에 관한 것으로, 옥시라세탐을 유효성분으로 함유하는 근육질환 개선, 치료 또는 예방용 조성물에 관한 것이다. 본 발명의 조성물은 근육질환을 예방, 치료 또는 개선시킬 수 있고, 특히 덱사메타손 처리에 의한 근위축 동물모델, 노화성 근위축(sarcopenia) 동물모델, 듀센형 근이영양증 동물모델 및 악액질 근육질환 세포모델 및 염증성 근육질환 세포모델에서의 개선, 예방, 치료효과를 확인한 바, 근육질환 예방 또는 치료용 약학 조성물, 식품 조성물 등으로 활용될 수 있다.

公开(公告)号：WO2022226312A1

公开(公告)日：2022-10-27

申请号：PCT/US2022/025959

申请日：2022-04-22

申请人： CLEAR CREEK BIO, INC.

发明人： KUMAR, Vikram, S. ,  HESSON, David, P. ,  DEMAREST, James, Francis

IPC分类号： A61P31/14 ,  A61K31/343 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/513

摘要： The invention provides methods of treating cancers and viral infections by providing a combination of agents that inhibit both nucleotide synthesis and nucleotide salvage in the cells of a subject to prevent cancer proliferation and viral replication. The invention provides methods of depleting nucleotide pools by using both inhibitors of dihydroorotate dehydrogenase (DHODH), such as brequinar, which block synthesis of pyrimidine-based nucleotides, in combination of one or more nucleotide salvage inhibitors, for example deoxycytidine kinase (dCK) inhibitors, Equilibrative nucleoside transporter (ENT) inhibitors, and Uridine-cytidine kinase (UCK) inhibitors, which inhibit salvage of purine and/or pyrimidine-based nucleotides or nucleosides

公开(公告)号：WO2022186328A1

公开(公告)日：2022-09-09

申请号：PCT/JP2022/009098

申请日：2022-03-03

申请人： 国立研究開発法人理化学研究所

发明人： 長田　裕之 ,  本山　高幸 ,  アブデルハキム　イスラム　アデル ,  二村　友史

IPC分类号： C07D207/273 ,  A61K31/4015 ,  A61P33/06 ,  C12P17/10

摘要： 本発明は、次式（Ｉ）： で示される化合物、及び前記化合物を含有する抗マラリア薬に関する。

公开(公告)号：WO2022145923A1

公开(公告)日：2022-07-07

申请号：PCT/KR2021/019942

申请日：2021-12-27

申请人： 주식회사 휴사이온

发明人： 주성수 ,  하나름 ,  유정민 ,  경영수 ,  전종갑 ,  정헌세 ,  장수길

IPC分类号： C07D211/86 ,  A61K31/45 ,  A61K31/495 ,  A61K31/4015 ,  A61K31/165 ,  C07C231/14 ,  C07D295/108 ,  C07D207/38 ,  C07C233/31 ,  C07C231/12

摘要： 본 발명은 피페론구민계 화합물을 유효성분으로 포함하는 바이러스 감염증의 예방 또는 치료용 약학적 조성물에 관한 것이다. 구체적으로, 본 발명에 따른 피페론구민계 화합물은 신종 코로나바이러스(SARS-CoV-2)의 감염을 저해함으로써, 바이러스의 감염, 특히 RNA 바이러스 감염증의 치료에 유용하게 사용될 수 있다.

公开(公告)号：WO2022017945A1

公开(公告)日：2022-01-27

申请号：PCT/EP2021/069880

申请日：2021-07-15

申请人： GW RESEARCH LIMITED

发明人： CHECKETTS, Daniel, Adam ,  CRAIG, Kevin, James

IPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/4015 ,  A61K31/551 ,  A61K45/06 ,  A61P25/08 ,  A61K31/4415 ,  A61K31/5513

摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with a SPATA5 mutation. In a further embodiment the types of seizures include tonic, myoclonic and focal seizures with impairment. Preferably the dose of CBD is between mg/kg/day to 50 mg/kg/day.

公开(公告)号：WO2022017936A1

公开(公告)日：2022-01-27

申请号：PCT/EP2021/069868

申请日：2021-07-15

申请人： GW RESEARCH LIMITED

发明人： CHECKETTS, Daniel, Adam ,  CRAIG, Kevin, James

IPC分类号： A61K31/05 ,  A61K31/19 ,  A61K31/197 ,  A61K31/4015 ,  A61K31/551 ,  A61K31/165 ,  A61K31/7048 ,  A61K31/27 ,  A61K31/352 ,  A61K45/06 ,  A61K31/4192 ,  A61K31/53 ,  A61K31/55 ,  A61P25/08 ,  A61P25/10 ,  A61P25/12

摘要： The present invention relates to the use of cannabidiol (CBD) for the treatment of seizures associated with rare epilepsy syndromes. In particular the seizures associated with rare epilepsy syndromes that are treated are those which are experienced in patients diagnosed with Heterotopia. In a further embodiment the types of seizures include tonic, tonic-clonic, atonic, absence and focal seizures without impairment. Preferably the dose of CBD is between 5 mg/kg/day to 50 mg/kg/day.